AlphAIAlphAI — Financial news for AI agents
prnewswire.comOCT 142 min read$VNDA

Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program

Vanda Pharmaceuticals (VNDA) reported that its Phase III study of VQW-765 for social anxiety disorder did not meet the primary endpoint, failing to show a significant difference from placebo. The study evaluated 546 adults and did not confirm earlier Phase II results. The company plans to analyze the full dataset before deciding next steps. VQW-765 is a novel alpha 7 nicotinic acetylcholine receptor partial agonist.

Original reporting
prnewswire.com
Published Oct 14, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program — source image
Source · prnewswire.com
Decision brief

The 30-second read

$VNDABearishMed
01

Why it matters

The Phase III failure removes a near‑term catalyst and puts the program on hold, likely triggering a sell‑off in VNDA shares.

02

Market read

First disclosure of a pivotal trial miss for a small‑cap biotech; material for traders watching biotech pipelines.

03

What to watch

Potential future data from the full dataset or alternative indications could revive the program.

Relevance 8/10Novelty 8/10Timing: today

Background

Vanda Pharmaceuticals (NASDAQ: VNDA) is a biopharma focused on novel therapies for unmet medical needs. VQW-765 is an α7‑nicotinic receptor partial agonist licensed from Novartis.

Company-level read

Ticker impact

$VNDABearishHigh confidence
Context

Vanda Pharmaceuticals reported its Phase III trial of VQW-765 failed to meet the primary endpoint for social anxiety disorder.

Expected impact

downward pressure as investors price in the failed study and program pause

Evidence & confidence

Phase III data are material for a biotech; a miss typically triggers a sell‑off, especially when the program is placed on hold.

Market effects

Sector

May dampen sentiment for other anxiety‑disorder biotech peers.

Regional

Limited to U.S. biotech sector.

Global

Low; impact confined to Vanda and similar small‑cap biotech stocks.

Counterpoint

What could challenge this read

If the company can pivot the asset to another indication, the drop could be overstated.

Key entities

  • company
    Vanda Pharmaceuticals Inc.

    Issuer of the failed Phase III trial.

  • executive
    Mihael H. Polymeropoulos, M.D.

    CEO who announced the trial results.

Read at source← All news

StoryVanda Pharmaceuticals reports Phase III failure of VQW‑765 for social anxiety disorder

Also covered by

1 outlet

Related articles

OCT 14
$VNDAHighAI 8/10

Vanda Pharmaceuticals stock falls after anxiety drug trial fails

Vanda Pharmaceuticals (VNDA) shares dropped 6.2% after its anxiety drug VQW-765 failed to meet the primary endpoint in a Phase III trial. The study did not show statistical significance in reducing distress levels in female participants with social anxiety disorder. The company plans to analyze the full dataset before deciding on next steps. VQW-765 was licensed from Novartis and is being developed for psychiatric disorders.

investing.com2 min
OCT 14
$VNDAMedAI 8/10

Vanda’s phase III trial for social anxiety drug fails

Vanda Pharmaceuticals (VNDA) reported that its phase III trial for VQW-765, a drug for social anxiety, failed to meet primary and secondary endpoints. The study showed no significant difference in distress levels between the drug and placebo. The company has paused the program pending further analysis. The drug was safe and well-tolerated, according to the company.

investing.com2 min
OCT 5
$VNDAMedAI 8/10

Wainwright reiterates Buy on Vanda stock after sleep disorder trial

H.C. Wainwright reiterated a Buy rating and $20 price target for Vanda Pharmaceuticals (VNDA) after positive Phase 3 trial results for its sleep disorder treatment. The stock is down over 10% in the past week, trading at $4.63. The study met its primary endpoint, with HETLIOZ shifting sleep onset 42.5 minutes earlier vs. placebo. Vanda reported a disappointing Q2 2026, missing earnings and revenue estimates, with an adjusted loss of $1.04 per share and revenue of $50.5 million.

investing.com2 min
SEP 30
$VNDAHighAI 8/10

Vanda Reports Positive Phase 3 Results For HETLIOZ In Delayed Sleep-Wake Phase Disorder; Stock Up

Vanda Pharmaceuticals (VNDA) reported positive Phase 3 results for HETLIOZ in treating Delayed Sleep-Wake Phase Disorder, meeting primary endpoints. HETLIOZ shifted sleep onset 37.1 minutes earlier vs. placebo. The company plans to discuss results with the FDA and submit an sNDA. HETLIOZ sales declined 66% YoY in Q2 2026, partly due to shipment timing. VNDA stock is up 10.14% in overnight trading.

rttnews.com2 min
SEP 29
$VNDAHighAI 9/10

Why is Vanda Pharmaceuticals stock surging today?

Vanda Pharmaceuticals (VNDA) stock rose 12% in after-hours trading to $5.63 after reporting positive phase III results for its Hetlioz treatment in delayed sleep-wake phase disorder. The trial met its primary endpoint, and the company plans to discuss the data with the FDA. If approved, Hetlioz would be the first FDA-approved medicine for this condition.

investing.com2 min